NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Socie... (dical needs by leveraging and expanding ...)

HOME >> MEDICINE >> TECHNOLOGY

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting

Date:5/7/2008

dical needs by leveraging and expanding its technology platforms to improve known molecules.

This press release contains forward-looking statements regarding the potential of the company's PEGylation technology platform and NKTR-118. These forward-looking statements involve important risks and uncertainties, including but not limited to: (i) preclinical testing and clinical trials for NKTR-118 are long, expensive and uncertain processes, (ii) because the NKTR-118 product development program is in the early phases of clinical development, the risk of failure is high and can occur at any stage of development, (iii) the company may fail to obtain regulatory approval of NKTR-118, (iv) potential competition from approved drugs or drugs under development that may be safe and effective for the same indication as that targeted by NKTR-118, and (v) the company's patent applications for NKTR-118 may fail to issue; patents that have issued may not be enforceable; or unanticipated intellectual property licenses from third parties may be required in the future. Other important risks and uncertainties are detailed in the company's reports and other filings with the SEC; including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise. No information regarding or presented at the scientific meetings referred to above (or contained at the Internet links provided herein) is intended to be incorporated by reference in this press release.

Contacts:

Tim Warner (650) 283-4915 or twarner@nektar.com

Stephan Herrera (415) 488-7699 or sherrera@nektar.com

Jennifer Ruddock (650) 631-4954 or

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
2. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
3. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
4. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
7. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
8. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
9. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
10. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
11. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies

Post Your Comments:

(Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading ... it has signed a three-year single source ... supply contracting company, for MAQUET,s market-leading VASOVIEW ... products assist healthcare providers in obtaining veins ... only small incisions. This allows for faster ...

(Date:12/16/2009)... Naurex Inc., a new clinical stage ... CNS disorders based on its novel GFPA NMDA ... a Phase I clinical trial of its lead ... subjects in the study. GLYX-13, a glycine ... the NMDA receptor, is initially being developed as ...

(Date:12/16/2009)... Texas, Dec. 16 Savara, Inc., an inhalation ... the second tranche in its Series A financing round, ... ,, Funds raised in the Series A ... the NanoCluster technology. ,, "We now have the ... performance of the NanoCluster technology," said Rob Neville, CEO ...

Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2 MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3 MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4 Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2 Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3 Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2 Solon Manufacturing Company Acquires PurFybr Brands 3B Adds Influenza Virus Diagnostic Swabs to Product Line 12710 1 Solon Manufacturing Company Acquires PurFybr Brands 3B Adds Influenza Virus Diagnostic Swabs to Product Line 12710 2 Pesticide Residue Common on Kitchen Floors 49522 1 Pesticide Residue Common on Kitchen Floors 49522 2 Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 1 Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 2 Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 3 Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 4

[0] MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices [0] Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression [0] Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent

... Finding May Refine Drug Targets for Personalized Treatments -, ... genes that increase the risk of developing inflammatory,bowel disease ... to identify the specific disease-causing,mutations in these new genes, ... be added to the list of genes already,known to ...

... trial showed prasugrel substantially reduced, risk of heart attack and stent ... ... Germany, Aug. 31 Patients who were,diabetic and diagnosed with acute ... attack if they were treated with prasugrel,vs. clopidogrel, according to a ...

Other Medicine Technology:New Genes Found for Inflammatory Bowel Disease in Children 2 New Genes Found for Inflammatory Bowel Disease in Children 3 New Genes Found for Inflammatory Bowel Disease in Children 4 Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel 2 Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel 3 Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel 4 Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel 5

New Genes Found for Inflammatory Bowel Disease in Children Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel

(Date:12/16/2009)... ANN ARBOR, Mich., Dec. 16 The most widely ... a finding that raises social justice questions that must ... benefit from stem cell advances, according to a University ... study of its kind, the U-M team analyzed 47 ... commonly used by stem cell researchers. The scientists determined ...

(Date:12/16/2009)... HealthSciences Institute will sponsor a new learning ... organizations who serve individuals at risk of, ... health plan, medical home and other provider ... noncommercial webinars on topics, solutions and case ... care improvement. Each webinar will include a ...

(Date:12/16/2009)... seven that increase susceptibility to disease , , WEDNESDAY, ... with increased susceptibility to leprosy have been identified ... researchers, who analyzed more than 10,000 DNA samples ... said their discovery highlights the important role that ... of leprosy. , "Though leprosy is not common, ...

(Date:12/16/2009)... teams led by the Wellcome Trust Sanger Institute announce ... All cancers are caused by mutations in the DNA ... lifetime. The studies, of a malignant melanoma and a ... the mutations in the genomes of two cancers. , ... year: almost all are associated with smoking. The number ...

(Date:12/16/2009)... University of Florida researchers at work on a ... to predict the spread of the disease using cell ... million calls to determine how often residents of Zanzibar ... of two islands off the coast of Tanzania in ... years. Its government commissioned the study as part of ...

Breaking Medicine News(10 mins):Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2 Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3 Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4 Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5 Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2 Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3 Health News:Leprosy Genes Identified 2 Health News:Lung cancer and melanoma laid bare 2 Health News:Lung cancer and melanoma laid bare 3 Health News:Lung cancer and melanoma laid bare 4 Health News:Lung cancer and melanoma laid bare 5 Health News:Lung cancer and melanoma laid bare 6 Health News:Scientists use cell phone records to predict spread of malaria 2 Health News:Scientists use cell phone records to predict spread of malaria 3

[0] U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines [1] New Learning Collaborative to Prepare Clinicians for Better Chronic Care [0] Leprosy Genes Identified [0] Lung cancer and melanoma laid bare [0] Scientists use cell phone records to predict spread of malaria

... June 5 Soaring gas prices are,a contributing factor ... on,the poorest and most vulnerable within the global community ... situation is particularly devastating in Ethiopia, one of the ... in 2007 and again in 2008,compounded the Ethiopian situation, ...

... ) today reported preliminary total retail drug,store sales for the four-week and seventeen-week periods ended May 29,2008., ... Periods ended May 29, 2008 ... Month Year to Date (Dollars ... (4 weeks) (17 weeks), Total retail drug store sales ...

... A Closer Look at The Value of,MRIs ... of,America,s (MSAA) website, http://www.msassociation.org . This three ... offering a first-hand,account on the experience of undergoing ... well as the importance of MRIs to monitor ...

... Benchmarking is not a luxury;,it is an activity that ... a survey analysis of 30 companies and in-depth interviews,with ... benchmarking in a,difficult economy., The complete study addresses ... the goals of benchmarking studies, how companies are,demonstrating value ...

... Forum to Explore Solutions Presented by The Massachusetts ... 5 "We are greatly,concerned in this state about ... of our returning veterans, the stress, depression and ... specter of rising levels of,domestic violence and suicide. ...

... entertainment and ... more, ... fitness and figure competitors Allison,Frahn and Tina Durkin, will represent GNC at ... Centre in Atlanta., Chad, part of the World Natural Bodybuilding Federation ...

Other Medicine News:Health News:Impact of Rising Gas, Food Prices Felt Globally 2 Health News:Longs Reports Preliminary May Retail Drug Store Sales 2 Health News:Photos: The Multiple Sclerosis Association of America Produces a Web Video on the Importance of MRIs 2 Health News:Demonstrating the Value of Benchmarking in an Uncertain Economy 2 Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2 Health News:Rite Aid Health and Beauty Expo to Showcase GNC Athletes 2

Impact of Rising Gas, Food Prices Felt Globally Longs Reports Preliminary May Retail Drug Store Sales Photos: The Multiple Sclerosis Association of America Produces a Web Video on the Importance of MRIs Demonstrating the Value of Benchmarking in an Uncertain Economy Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans Rite Aid Health and Beauty Expo to Showcase GNC Athletes

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Electrophoresis, Protein, Serum Electrolytes, Urine Electrolyte Panel Electrolyte & Osmolality Profile, Fecal

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Socie...(dical needs by leveraging and expanding ...),Health